Skip to main content
Fig 3. | Cost Effectiveness and Resource Allocation

Fig 3.

From: Cost-effectiveness of paclitaxel, doxorubicin, cyclophosphamide and trastuzumab versus docetaxel, cisplatin and trastuzumab in new adjuvant therapy of breast cancer in china

Fig 3.

Results of cost-effectiveness analyses for the Breast cancer patients. The vertical axes represent the lifetime cumulative cost and the horizontal axes represent the quality-adjusted life years (QALYs) gained. The AC-TH strategy is the dominant strategy because it is the most effective and the least expensive of the two alternative strategies

Back to article page

Cost Effectiveness and Resource Allocation

ISSN: 1478-7547

Contact us